Veradermics Raises $295M in Upsized IPO, Exceeding Expectations

Event summary

  • Veradermics closed its upsized IPO on February 5, 2026, raising $294.8M from 17.3M shares sold at $17.00 per share.
  • Underwriters fully exercised their option to purchase an additional 2.3M shares.
  • Shares began trading on the NYSE under the ticker symbol 'MANE' on February 4, 2026.
  • The offering was led by Jefferies, Leerink Partners, Citigroup, and Cantor as joint book-running managers.

The big picture

Veradermics' successful upsized IPO reflects strong investor appetite for late-stage dermatology therapeutics, particularly in the aesthetic space. The $295M raise positions the company to advance its lead candidate, VDPHL01, while expanding its portfolio in a market increasingly focused on non-invasive and oral treatments. The deal underscores the growing interest in dermatology as a high-growth sector within biopharma.

What we're watching

Clinical Progress
How the $295M capital infusion will accelerate Veradermics' lead program, VDPHL01, an oral treatment for pattern hair loss.
Market Performance
Whether Veradermics can sustain momentum post-IPO, given the competitive landscape in aesthetic dermatology.
Portfolio Expansion
The pace at which Veradermics will develop its pipeline beyond VDPHL01, including potential medical dermatology candidates.

Related topics

IPO